Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis

BMC Clinical Pathology

Volumn 12, Issue , 2012, Pages

  Le Rhun, Emilie ^a,b   Massin, Frédéric ^c   Tu, Qian ^c   Bonneterre, Jacques ^a,d   Bittencourt, Marcelo De Carvalho ^c,e   Faure, Gilbert C ^c,e  

^a CENTRE OSCAR LAMBRET   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d UNIV LILLE   (France)

^e UNIVERSITÉ DE LORRAINE   (France)

Author keywords

CellSearch technology; CSF cytology; Immunomagnetic enrichment; Leptomeningeal metastasis; Meningeal carcinomatosis; Neoplastic meningitis

Indexed keywords

CAPECITABINE; CYTARABINE; CYTOKERATIN; LAPATINIB; NAVELBINE; PRESERVATIVE;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CEREBROSPINAL FLUID ANALYSIS; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FOLLOW UP; HUMAN; INFORMATION PROCESSING; LEPTOMENINGEAL METASTASIS; MEDICAL TECHNOLOGY; METASTASIS; METHODOLOGY; MORPHOLOGY; NERVE FIBER; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY;

EID: 84872104239     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-12-21     Document Type: Article

References (24)

1. Leptomeningeal metastasis. Chamberlain MC, Curr Opin Oncol 2010 22 627 635 10.1097/CCO.0b013e32833de986 20689429
2. New strategies in the management of leptomeningeal metastases. Groves MD, Arch Neurol 2010 67 305 312 10.1001/archneurol.2010.18 20212228
3. Breast cancer leptomeningeal metastasis-the role of multimodality treatment. Rudnicka H, Niwinska A, Murawska M, J Neurooncol 2007 84 57 62 10.1007/s11060-007-9340-4 17310266
4. Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy. Clatot F, Philippin-Lauridant G, Ouvrier MJ, Nakry T, Laberge-Le-Couteulx S, Guillemet C, Veyret C, Blot E, J Neurooncol 2009 95 3 421 426 10.1007/s11060-009-9940-2 19557501
5. Survival of breast cancer patients with meningeal carcinomatosis. Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, Laurence V, Livartowski A, Mignot L, Diéras V, Ann Oncol 2010 21 11 2183 2187 10.1093/annonc/mdq232 20430906
6. Meningeal carcinomatosis in breast cancer: prognostic factors and outcomes. de Azevedo CR, Cruz MR, Chinen LT, Peres SV, Peterlevitz MA, de Azevedo Pereira AE, Fanelli MF, Gimenes DL, J Neurooncol 2011 104 2 565 572 10.1007/s11060-010-0524-y 21234642
7. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Lee S, Ahn HK, Park YH, Nam Do H, Lee JI, Park W, Choi DH, Huh SJ, Park KT, Ahn JS, Im YH, Breast Cancer Res Treat 2011 129 3 809 817 10.1007/s10549-011-1682-0 21785952
8. Prospective follow-up of a cohort of 112 patients with leptomeningeal metastases of breast cancer recruited from 2007 to 2011: prognostics factors. Zairi F, Kotecki N, Rodrigues I, Baranzelli MC, Andre C, Dubois F, Devos P, Faivre-Pierret M, Assaker R, Bonneterre J, Le Rhun E, J Clin Oncol 2012 General Poster Session, Central Nervous System, abstract 2070, American Society of Clinical Oncology, Annual Meeting, 2012; June, Chicago, IL. should be changed in General Poster Session, Central Nervous System Tumors, abstract 2070, American Society of Clinical Oncology, Annual Meeting, 2012; June Chicago, IL. Citation: J Clin Oncol 30, 2012 (suppl; abstr 2070)
9. Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M, J Cancer Res Clin Oncol 2010 136 1729 1735 10.1007/s00432-010-0831-x 20204406
10. Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. Chamberlain MC, Glantz M, Groves MD, Wilson WH, Semin Oncol 2009 36 35 S45 19660682
11. Leptomeningeal metastases in the MRI era. Chamberlain MC, Neurology 2011 76 200 201 10.1212/WNL.0b013e3181fac738 21220726
12. A standardized protocol for flow cytometric analysis of cells isolated from cerebrospinal fluid. Dux R, Kindler-Röhrborn A, Annas M, Faustmann P, Lennartz K, Zimmermann CW, J Neurol Sci 1994 121 74 78 10.1016/0022-510X(94) 90159-7 7510788
13. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Glantz MJ, Cole BF, Glantz LK, et al. Cancer 1998 82 733 739 10.1002/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z 9477107
14. Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers. Corsini E, Bernardi G, Gaviani P, Silvani A, de Grazia U, Ciusani E, Croci D, Salmaggi A, Clin Chem Lab Med 2009 47 874 879 19453289
15. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. Groves M, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli M, Yung WK, Liu TJ, J Neurooncol 2009 94 229 234 10.1007/s11060-009-9819-2 19267183
16. Identification of leptomeningeal metastasis-related proteins in cerebro-spinal fluid of patients with breast cancer by a combination of MALDI-TOF, MALDI-FTICR and nanoLC-FTICR MS. Römpp A, Dekker L, Taban I, Jenster G, Boogerd W, Bonfrer H, Spengler B, Heeren R, Smitt PS, Luider TM, Proteomics 2007 7 474 481 10.1002/pmic.200600719 17274072
17. Detection of cancer cells in the cerebrospinal fluid: current methods and future directions. Weston CL, Glantz MJ, Connor JR, Fluids Barriers CNS 2011 8 14 10.1186/2045-8118-8-14 21371327
18. Known and emerging biomarkers of leptomeningeal metastasis and its response to treatment. Walbert T, Groves MD, Future Oncol 2010 6 287 297 10.2217/fon.09.167 20146587
19. Cytomics-importance of multimodal analysis of cell function and proliferation in oncology. Tárnok A, Bocsi J, Brockhoff G, Cell Prolif 2006 39 495 505 10.1111/j.1365-2184.2006.00407.x 17109634
20. Significance of Circulating Tumor Cells Detected by the Cell Search System in Patients with Metastatic Breast Colorectal and Prostate Cancer. Miller MC, Doyle GV, Terstappen LW, J Oncol 2010 2010 617421 20016752
21. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Jänicke F, Jackson S, Gornet T, Cristofanilli M, Clin Cancer Res 2007 13 920 928 10.1158/1078-0432.CCR-06-1695 17289886
22. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant disease. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibe AG, Uhr JW, Terstappen LW, Cin Cancer Res 2004 10 20 6897 6904
23. Immunomagnetic platform technology (IMPT) for the diagnosis of leptomeningeal metastasis in solid tumors (LMST). Nayak L, Fleisher M, Gonzalez-Espinoza R, Reiner AS, Panageas K, Lin O, Liu C, DeAngelis LM, Omuro AM, ASCO Poster Dis Sess 2010 Abstract Number: 2032. should be changed in Poster Discussion Session, Central Nervous System Tumors, abstract 2032, American Society of Clinical Oncology, Annual Meeting, 2010; June, Chicago, IL. Citation: J Clin Oncol 28:15s, 2010 (suppl; abstr 2032)
24. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, El-Deiry WS, Oncotarget 2011 2 752 760 21987585